-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Enterprise News] On April 13, Nuocheng Jianhua announced that its application for listing on the Science and Technology Innovation Board was approved
.
The company is an innovative drug company focusing on the independent research and development of drugs for malignant tumors and autoimmune diseases.
It was listed on the Hong Kong Stock Exchange in March 2020
.
The listing of Nuocheng Jianhua on the Science and Technology Innovation Board plans to raise 4 billion yuan, of which half of the funds will be used for new drug research and development
.
Nuocheng Jianhua has a rich R&D pipeline, and its self-developed Class 1 innovative drug, orbrutinib, is also the company's core product.
It has been approved by the State Food and Drug Administration for the treatment of relapsed/refractory chronic Lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients and relapsed/refractory mantle cell lymphoma (MCL) patients will be included in the National Medical Insurance List in 2021 to achieve high volume
.
The company is actively carrying out the commercialization of Orelabrutinib in China.
As of December 31, 2021, Orbrutinib has rapidly covered more than 1,000 hospitals in more than 260 cities.
During the reporting period, the company also cooperated with Bojian on Orbutinib Biogen has entered into a licensing and collaboration agreement for the treatment of multiple sclerosis (MS), and received a US$125 million down payment from Biogen
.
In 2021, the product brought in good revenue, with a total sales of 241 million yuan
.
It is reported that the cooperation agreement between Nuocheng Jianhua and Bojian stipulates that when the development milestones and commercialization milestones agreed in the cooperation are reached, Nuocheng Jianhua is eligible to receive up to $812.
5 million in potential clinical development milestones and commercial milestone payments, and at the same time Will also be eligible for tiered royalties ranging from low to high in the tens of percent of potential future net sales
.
It is predicted that the peak global sales of this indication is expected to reach US$3 billion in the future
.
At present, there are more indications for Orbrutinib on the way
.
Among them, the new indication marketing application for the treatment of relapsed/refractory Waldenström macroglobulinemia has been accepted by the State Food and Drug Administration
.
In the first half of 2022, Nuocheng Jianhua also plans to submit a new indication marketing application for relapsed/refractory marginal zone lymphoma
.
In addition, Nuocheng Jianhua also targets relapsed/refractory mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, systemic lupus erythematosus, diffuse large B-cell lymphoma MCD subtype, primary Clinical studies are carried out in multiple indications such as immune thrombocytopenia and neuromyelitis optica spectrum diseases, and the combination therapy of orelabrutinib and octuzumab is explored
.
In general, the clinical value of orelabrutinib still has room to be tapped, and it may have greater growth potential in the future
.
In addition to orelabrutinib, Nuocheng Jianhua has a batch of products in the clinical stage, of which 9 products are in the phase I/II/III clinical trial stage, and 6 products are in the preclinical stage
.
The research and development of new drugs is characterized by a long cycle and high investment.
With the clinical advancement of more new drugs under research and the successive development of multiple global multi-center clinical trials, the pressure on research and development investment will also increase
.
In recent years, Nuocheng Jianhua's R&D investment has shown a growing trend.
Financial data shows that in 2019, 2020 and 2021, Nuocheng Jianhua's R&D investment reached 234 million yuan, 423 million yuan and 733 million yuan respectively, of which 2021 R&D investment accounts for about 70% of revenue
.
The company's IPO on the Science and Technology Innovation Board plans to raise 4 billion yuan, of which 2.
151 billion yuan will be invested in new drug research and development, accounting for more than half
.
According to incomplete statistics, since 2022, the number of pharmaceutical companies that have attended the IPO meeting on the Science and Technology Innovation Board has reached 7.
In addition to Nuocheng Jianhua, the pharmaceutical companies that have attended the meeting this year also include Xuantai Pharmaceutical, Yifang Bio, and Myland.
Medical, Mengke Pharmaceutical, Chuang Electrophysiology,
etc.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The company is an innovative drug company focusing on the independent research and development of drugs for malignant tumors and autoimmune diseases.
It was listed on the Hong Kong Stock Exchange in March 2020
.
The listing of Nuocheng Jianhua on the Science and Technology Innovation Board plans to raise 4 billion yuan, of which half of the funds will be used for new drug research and development
.
Nuocheng Jianhua has a rich R&D pipeline, and its self-developed Class 1 innovative drug, orbrutinib, is also the company's core product.
It has been approved by the State Food and Drug Administration for the treatment of relapsed/refractory chronic Lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) patients and relapsed/refractory mantle cell lymphoma (MCL) patients will be included in the National Medical Insurance List in 2021 to achieve high volume
.
The company is actively carrying out the commercialization of Orelabrutinib in China.
As of December 31, 2021, Orbrutinib has rapidly covered more than 1,000 hospitals in more than 260 cities.
During the reporting period, the company also cooperated with Bojian on Orbutinib Biogen has entered into a licensing and collaboration agreement for the treatment of multiple sclerosis (MS), and received a US$125 million down payment from Biogen
.
In 2021, the product brought in good revenue, with a total sales of 241 million yuan
.
It is reported that the cooperation agreement between Nuocheng Jianhua and Bojian stipulates that when the development milestones and commercialization milestones agreed in the cooperation are reached, Nuocheng Jianhua is eligible to receive up to $812.
5 million in potential clinical development milestones and commercial milestone payments, and at the same time Will also be eligible for tiered royalties ranging from low to high in the tens of percent of potential future net sales
.
It is predicted that the peak global sales of this indication is expected to reach US$3 billion in the future
.
At present, there are more indications for Orbrutinib on the way
.
Among them, the new indication marketing application for the treatment of relapsed/refractory Waldenström macroglobulinemia has been accepted by the State Food and Drug Administration
.
In the first half of 2022, Nuocheng Jianhua also plans to submit a new indication marketing application for relapsed/refractory marginal zone lymphoma
.
In addition, Nuocheng Jianhua also targets relapsed/refractory mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, systemic lupus erythematosus, diffuse large B-cell lymphoma MCD subtype, primary Clinical studies are carried out in multiple indications such as immune thrombocytopenia and neuromyelitis optica spectrum diseases, and the combination therapy of orelabrutinib and octuzumab is explored
.
In general, the clinical value of orelabrutinib still has room to be tapped, and it may have greater growth potential in the future
.
In addition to orelabrutinib, Nuocheng Jianhua has a batch of products in the clinical stage, of which 9 products are in the phase I/II/III clinical trial stage, and 6 products are in the preclinical stage
.
The research and development of new drugs is characterized by a long cycle and high investment.
With the clinical advancement of more new drugs under research and the successive development of multiple global multi-center clinical trials, the pressure on research and development investment will also increase
.
In recent years, Nuocheng Jianhua's R&D investment has shown a growing trend.
Financial data shows that in 2019, 2020 and 2021, Nuocheng Jianhua's R&D investment reached 234 million yuan, 423 million yuan and 733 million yuan respectively, of which 2021 R&D investment accounts for about 70% of revenue
.
The company's IPO on the Science and Technology Innovation Board plans to raise 4 billion yuan, of which 2.
151 billion yuan will be invested in new drug research and development, accounting for more than half
.
According to incomplete statistics, since 2022, the number of pharmaceutical companies that have attended the IPO meeting on the Science and Technology Innovation Board has reached 7.
In addition to Nuocheng Jianhua, the pharmaceutical companies that have attended the meeting this year also include Xuantai Pharmaceutical, Yifang Bio, and Myland.
Medical, Mengke Pharmaceutical, Chuang Electrophysiology,
etc.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
